AAM Condemns ‘Build Back Better 2.0’ Due To Off-Patent Impact
US Draft Drug Legislation Could Complicate Market Entry For Generics And Biosimilars
The Association for Accessible Medicines has criticized draft legislation regarding US drug pricing negotiations for the impact proposed new laws could have on generic and biosimilar drugs.
You may also be interested in...
The AAM has criticized the passage of the US Inflation Reduction Act though the country’s Senate, claiming that the legislation’s “flawed framework for government price setting” will chill generic and biosimilar development and will reduce patient access.
Senators Maria Cantwell and Chuck Grassley have introduced a bill which would limit pharmacy benefit managers’ ability to engage in “unfair and deceptive” business practices, a move which has been welcomed by the Biosimilars Forum.
Pharmacy benefit managers often fail to encourage the use of generic and biosimilar medications and in fact undermine patient access to these more affordable drugs, the Association for Accessible Medicines has told the US Federal Trade Commission.